lung cancer, colon cancer, lymphoma, multiple myeloma, etc.
Conditions
Interventions
Sponsors
307th Hospital of People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients are diagnosed as lung cancer/ colon cancer in cytodiagnosis or tissue diagnosis; 2. With measurable lesions (except single dose); 3. KPS >= 70; 4. Aged >=18 when the consent is obtained; 5. Patients who are expected to survive for more than 3 months from the date of first administration; 6. In clinical examination be guaranteed as below: WBC >= 3.0*10^9/L, platelet >=75*10^9/L, hemoglobin >=9.5g/dLserum ALT/AST <=2.5 times upper limit of normal valueBUN/Cr <=1.5 times upper limit of normal valueTotal bilirubin with normal value (2.0-20.0umol /L); 7. HBV/HCV negative; 8. Patients who have not received pre-treatment more than 4 weeks before registration; 9. With written consent of the patient to participate in the trial; 10.The fertility in female patients with a negative pregnancy test.
Exclusion criteria
Exclusion criteria: 1. Patients with active infectious diseases or potential serious complications; 2. Pregnant women, or lactating women; 3. Patients with a previous history of serious allergy on study drugs(CPT protein, mannitol, SC, DSP, MSP); 4. Patients with pneumonia failure, heart failure, renal failure or liver failure; 5. Patients with poor compliance; 6. Patients could not describe the treatment response; 7. Patients that have participated in other clinical trials within 4 weeks before enrolled in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PK;DLT;MTD;AE; | — |
Countries
China
Contacts
Public ContactSantai Song
307 hospital of People's Liberation Army
Outcome results
None listed